Observational Study: Biomarker Research for Tamoxifen Pharmacogenetics Among Asian Breast Cancer Patients
18 Years
N/A
Female
Poisoning by, Adverse Effect of and Underdosing of Tamoxifen
Trial Information
Observational Study: Biomarker Research for Tamoxifen Pharmacogenetics Among Asian Breast Cancer Patients
The investigators investigated the prognostic and/or predictive value of genetic
polymorphisms of enzymes involved in tamoxifen metabolism for the treatment outcome among
Asian breast cancer patients.
Inclusion Criteria:
- incident breast cancer patients who underwent surgery
Exclusion Criteria:
- previous cancer history before breast cancer diagnosis
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Retrospective
Outcome Measure:
Association between genetic polymorphisms of CYP2D6, CYP2C19, and CYP3A5 and disease free survival among tamoxifen treated breast cancer patients
Outcome Description:
Association between genetic polymorphisms of CYP2D6, CYP2C19, and CYP3A5 and disease free survival among tamoxifen treated breast cancer patients
Outcome Time Frame:
five years
Safety Issue:
No
Principal Investigator
JaeGook Shin, MD,PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Inje University
Authority:
Korea: Institutional Review Board
Study ID:
09-140
NCT ID:
NCT01181518
Start Date:
August 2010
Completion Date:
December 2015
Related Keywords:
- Poisoning by, Adverse Effect of and Underdosing of Tamoxifen
- Tamoxifen
- Pharmacogenomics
- Breast cancer
- Breast Neoplasms
- Poisoning
Name | Location |
|---|
